Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18358741 | 0.88 | CA9 (0.45) | CA9ALDH1A1HPGDNPSR1NR1H2 | |
| SCHEMBL17259224 | 0.87 | CHRNA7 (0.58) | CA9GABRA2GABRB2ALDH1A1SMN1; SMN2 | |
| SCHEMBL17259268 | 0.85 | MAPT (0.47) | CA9KMT2AMAPTNR1H2FAAH | |
| SCHEMBL1779589 | 0.83 | CA9 (0.59) | CA9GABRA2GABRB2GAAKMT2A | |
| SCHEMBL4011177 | 0.83 | RPA1 (0.58) | KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL14288144 | 0.82 | FAAH (0.58) | CA9GABRA2GABRB2GAAKMT2A | |
| SCHEMBL28804760 | 0.81 | CA9 (0.57) | CA9GABRA2GABRB2GAAKMT2A | |
| SCHEMBL9630738 | 0.81 | CA9 (0.77) | CA9GAAKMT2AMAPTFAAH | |
| SCHEMBL17259242 | 0.81 | SIRT2 (0.49) | CA9KMT2AALDH1A1TSHRFAAH | |
| SCHEMBL4009954 | 0.80 | PLA2G10 (0.48) | KMT2AALDH1A1SMN1; SMN2HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493423-B2 | Compounds capable of inhibiting voltage gated calcium ion channel, and pharmaceutical compositions comprising the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-11-15 | — | — | US | disclosed |
| US-20150329533-A1 | COMPOUNDS CAPABLE OF INHIBITING VOLTAGE GATED CALCIUM ION CHANNEL, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-11-19 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009011850-A2 | NOVEL THERAPEUTIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009011850-A2 | NOVEL THERAPEUTIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329533-A1 | COMPOUNDS CAPABLE OF INHIBITING VOLTAGE GATED CALCIUM ION CHANNEL, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CACNA1B, CACNA1F, CACNA1G | CA9 1762/4885GABRA2 202/4885GABRB2 179/4885 |
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | CA9 4575/4885GABRA2 4670/4885GABRB2 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.